Genprex Inc SEC Filings

Genprex, Inc. reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement. The Panel also approved an exception giving Genprex until December 31, 2025 to demonstrate long-term compliance with the Nasdaq stockholders’ equity requirement, with the possibility of further extension to February 9, 2026 at the Panel’s discretion.

The Panel may reconsider this exception if new events make continued listing inadvisable, and there is no assurance of any extension beyond December 31, 2025. Genprex states it believes it will need to complete additional capital raising transactions to regain compliance with the stockholders’ equity requirement, and notes there is no guarantee such financing will be available on acceptable terms, or at all.

Genprex, Inc. has filed an S-1 registering the resale of up to 1,280,088 shares of common stock issuable upon exercise of outstanding warrants by selling stockholders. The company’s common stock outstanding was 2,318,894 shares as of November 19, 2025, and would be 3,598,982 shares if all registered warrants are exercised. Genprex will not receive any proceeds from stockholder resales, but will receive cash only if the warrants are exercised.

Genprex is a clinical-stage gene therapy company developing its REQORSA oncology platform for non-small cell and small cell lung cancer, where key trials have FDA Fast Track and Orphan Drug designations, and a diabetes gene therapy program licensed from the University of Pittsburgh. Recent financing steps include a 1-for-50 reverse stock split, October 2025 registered direct offerings with accompanying private warrants, a $12.5 million equity line of credit, and sales under an ATM facility to support ongoing trials and preclinical work.

Genprex, Inc. filed a prospectus supplement for an at-the-market offering of additional common stock with an aggregate offering price of up to $75,000,000 under its existing agreement with H.C. Wainwright & Co., LLC.

This supplement updates the prior ATM prospectus documents and must be read together with them. Genprex has previously sold 796,065 shares of common stock for aggregate gross proceeds of $14,796,375 under the same Sales Agreement. A legal opinion from Lowenstein Sandler LLP covering the validity of the newly registered shares is included as an exhibit.

Genprex, Inc. is registering the offer and sale of up to $75,000,000 of additional common stock under an at-the-market offering agreement with H.C. Wainwright & Co. This prospectus supplement updates prior prospectuses and reflects a one-for-fifty reverse stock split of Genprex’s common stock effective October 21, 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol GNPX, and the last reported sale price on November 21, 2025 was $3.00 per share. The securities are described as involving a high degree of risk, with detailed risk factors incorporated by reference.

Genprex, Inc. reported that it has added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of lead drug candidate REQORSA Gene Therapy in lung cancer. The company also plans to add and open additional Acclaim trial sites over the coming months to reach more patients and speed enrollment.

Acclaim-1 is a Phase 1/2 trial in late-stage non-small cell lung cancer with EGFR mutations combining REQORSA with Tagrisso, with a Phase 2a expansion targeting about 33 patients and an interim analysis after 19 patients, which Genprex currently expects to fully enroll in the first half of 2026; the trial has FDA Fast Track Designation. Acclaim-3 is a Phase 1/2 trial in extensive stage small cell lung cancer combining REQORSA with Tecentriq as maintenance therapy, with Phase 2 expansion for about 50 patients and an interim analysis after the 25th patient reaches 18 weeks of follow-up, also expected to reach that enrollment milestone in the first half of 2026, and benefits from FDA Fast Track and Orphan Drug Designations.

Genprex, Inc. reported that the U.S. Patent and Trademark Office has granted a patent covering the use of its lead drug candidate, REQORSA Gene Therapy (quaratusugene ozeplasmid), in combination with PD‑L1 antibodies such as Tecentriq, with protection extending through 2037. This patent is intended to secure exclusivity for this cancer treatment combination by preventing competitors from making, using or selling the same drug combination.

The company highlighted that REQORSA is being studied in the Acclaim‑3 Phase 1/2 trial as maintenance therapy with Tecentriq for patients with extensive stage small cell lung cancer. Phase 1 dose escalation showed REQORSA was generally well tolerated with no dose‑limiting toxicities, and the Phase 2 expansion is expected to enroll about 50 patients. The primary goal is to assess 18‑week progression‑free survival, with an interim analysis planned after the 25th patient reaches 18 weeks of follow up in the first half of 2026. Acclaim‑3 is supported by FDA Fast Track and Orphan Drug designations.

Genprex, Inc. filed a Form S-8 registering 130,000 shares of common stock issuable under its 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).

The registered amount gives effect to the 1-for-50 reverse stock split effective October 21, 2025 and follows stockholder approval at the annual meeting held August 15, 2025. Prior S-8 registrations are incorporated by reference, and previously registered shares were adjusted for the 1-for-50 split and the 1-for-40 reverse split effective February 2, 2024.

Genprex, Inc. (GNPX) filed its Q3 2025 10‑Q, reporting continued operating losses and active financing to fund clinical programs. The company posted a Q3 net loss of $3,799,240 on operating expenses of $3,345,913, improving from a net loss of $4,315,987 a year ago. For the nine months ended September 30, 2025, net loss was $12,438,742.

Liquidity: Cash and cash equivalents were $1,103,315 as of September 30, 2025. Year‑to‑date, the company used $11,212,938 in operating cash and raised $10,714,593 via equity (including $6,895,947 from the 2023 ATM and $3,818,631 from the 2025 ELOC). Management states current cash is sufficient into March 2026, yet also discloses substantial doubt about continuing as a going concern without further financing.

Capital structure: Shares outstanding were 1,004,247 as of September 30, 2025; a 1‑for‑50 reverse split was completed on October 21, 2025. An ELOC derivative liability of $243,000 was recorded. Pipeline: REQORSA programs Acclaim‑1 (NSCLC) and Acclaim‑3 (ES‑SCLC) are in Phase 2 expansion; both have FDA Fast Track, and Acclaim‑3 also holds Orphan Drug Designation. Interim analyses are planned in 2026.

Genprex, Inc. filed a prospectus supplement for an at‑the‑market offering of up to $11,495,368 of common stock under its Sales Agreement with H.C. Wainwright & Co., to be sold from time to time.

The company updated its public float to $81.7 million as of November 7, 2025, calculated from 1,944,732 shares held by non‑affiliates at $42.00 (the October 15, 2025 closing price), and stated it is no longer subject to General Instruction I.B.6 sales limitations. Through the date hereof, it has sold 492,508 shares under the Sales Agreement pursuant to prior prospectuses. The supplement also reflects a 1‑for‑50 reverse stock split effective October 21, 2025. Genprex’s common stock trades on Nasdaq as “GNPX”; the last reported sale price on November 10, 2025 was $4.00 per share.